Growth FailureOPTIGROWNCT02999945
Optimal Growth of Preterm Infants With Growth Restriction
A study testing SGA-enhanced nutrients, IUGR-enhanced nutrients and SGA-standard nutrients in people with Growth Failure and Adiposity, run by Medical University of Vienna.
Trial summary
In this prospective randomized controlled multi center trial the investigators stratify "Very Low Birthweight " (VLBW)-infants with growth retardation in small for gestational age (SGA) or intrauterine growth restricted (IUGR) - infants and aim to investigate the impact of a nutritional management with enhanced… Read more about this study
- Who is it for?
- Ages Up to 42 weeksHealthy volunteers can take part
- Conditions the study is for
- Growth Failure, Adiposity, Diabetes
- What is being tested?
- SGA-enhanced nutrients, IUGR-enhanced nutrients and SGA-standard nutrients
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Mar 2019to Jan 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 42 weeks
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Preterm infants with a birth weight <1500g and birth weight <10th percentile.
- Weight at term <10th percentile
- Informed consent
Who cannot join
- Genetic or metabolic diseases with the primary effect on growth
- Necrotizing enterocolitis
- Intraventricular hemorrhage (IVH) >Grade II
- Periventricular leukomalacia (PVL) Stage III
- Genetic or metabolic disorders
- Bronchopulmonary dysplasia
About this study
Official title: Body Composition, Metabolic Programming and Long Term Outcome of Growth Restricted Preterm Infants Under Different Nutritional Management A Prospective Randomized Controlled Multicenter Trial
In this prospective randomized controlled multi center trial the investigators stratify "Very Low Birthweight " (VLBW)-infants with growth retardation in small for gestational age (SGA) or intrauterine growth restricted (IUGR) - infants and aim to investigate the impact of a nutritional management with enhanced nutrients from discharge up to the 52nd week of postconceptional age on growth, body composition, metabolic programming, metabolomics, microbiome and long term neurodevelopmental outcome. In this study, the investigators will evaluate the difference in metabolic profiles of SGA and IUGR preterm infants. The investigators will further longitudinally assess, how different nutritional interventions affect the altered pathways in the first year of life and identify, in combination with data available from metabolic markers, microbiome and breast milk analysis, potential pathways resulting in increased disease risk later in life.
Read the detailed description
Prematurity is the leading cause for mortality and morbidity in newborns with very low birth weight (VLBW) infants (< 1500g birth weight) at highest risk. Ten to thirty percent of VLBW infants are also born too small for their gestational age defined by a birth weight below the 10th percentile. In daily neonatal intensive care, consequential long term-follow up and most studies all growth restricted premature infants are treated the same, importantly this includes the nutritional management after birth. However, different groups of patients with different causal pathologies are subsumed under the definition growth restriction or born too small. One group of growth restricted patients refers to the infants born constitutionally small or small for gestational age (SGA). The other group refers to infants with an intrauterine growth restriction (IUGR) caused by a complex antenatal pathology. Consequently, the nutritional management after birth is very important to minimize the potential risk for developing obesity, diabetes and cardiovascular diseases later in life and to achieve optimal growth. So far we do not consider the different underlying pathomechanisms of growth restriction in our nutritional concepts for preterm infants and therefore cause long-term consequences. The European society of pediatric gastroenterology, hematology and nutrition (ESPGHAN) recommends to feed enhanced nutrients up to 52nd week of gestation in all growth restricted preterm infants- regardless if they are SGA or IUGR premature. Actually, reliable data guaranteeing that the recommended "enhanced nutrients strategy" providing extra nutrients up to 52 weeks for SGA and IUGR infants is safe and effective for both groups in terms of long-term growth and metabolic programming are lacking.
A total of 348 preterm infants born and discharged below the 10th percentile at term will be included in the study and stratified according to SGA or IUGR by a combination of antenatal ultrasound parameters and growth parameters (including 10% screening failures and 20% drop out. Furthermore IUGR and SGA growth restricted preterm infants will be stratified according to breastfeeding or formula feeding and randomized in one of the following groups: Standard nutrients group (breastfeeding or starter formula) or Enhanced nutrients group (fortified breast milk or post-discharge formula. Body composition measurements will be performed by air displacement plethysmography - a non-invasive method. Anthropometric measurements will be performed by measuring weight, height and head circumference. Furthermore, parameters of metabolic programming, metabolomics, the stool microbiome and neurodevelopmental outcome will be determined. Additionally, the stool microbiome will be characterized from infant stool samples and compared between the two groups. After an interventional period of three months infants will be followed up until 2 years of age.
- Conditions
- Growth Failure, Adiposity, Diabetes, Neurologic Deficits
- Being tested
- SGA-enhanced nutrients, IUGR-enhanced nutrients, SGA-standard nutrients, IUGR-standard nutrients
- Keywords
- preterm infants, SGA infants, IUGR infants, growth, body composition, metabolomics, microbiome, adiposity markers, metabolic programming, neurodevelopmental outcome
- Medical subject headings
- Failure to Thrive, Obesity, Diabetes Mellitus, Neurologic Manifestations
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SGA-enhanced nutrientsDietary supplement
Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
IUGR-enhanced nutrientsDietary supplement
Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
SGA-standard nutrientsOther
Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
IUGR-standard nutrientsOther
Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
| Study group | Role | What they receive |
|---|---|---|
| SGA-enhanced nutrients | Active comparator | Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term) Receives: Dietary Supplement: SGA-enhanced nutrients |
| SGA-standard nutrients | Other | Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term). Receives: Other: SGA-standard nutrients |
| IUGR-enhanced nutrients | Active comparator | Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term Receives: Dietary Supplement: IUGR-enhanced nutrients |
| IUGR-standard nutrients | Other | Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term). Receives: Other: IUGR-standard nutrients |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fat Free Mass
Fat free mass measured by body plethysmography
Measured: 3 months
Secondary outcomes (15)
anthropometry-length
length in cm
Measured: 24 months
anthropometry-weight
weight in grams
Measured: 24 months
anthropometry-HC
head circumference in cm
Measured: 24 months
anthropometry-z-score
z-scores
Measured: 24 months
parameters of metabolic programming- IGF1
IGF-1in ng/ml
Measured: 12 months
parameters of metabolic programming-IGF3
IGF-3 in ng/ml
Measured: 12 months
parameters of metabolic programming-IGF-BP
IGF-BP in ng/ml
Measured: 12 months
parameters of metabolic programming-Leptin
Leptin in ng/ml
Measured: 12 months
parameters of metabolic programming-Adiponectin
Adiponectin in mcg/ml
Measured: 12 months
neurodevelopmental outcome
Bayley scales
Measured: 24months
metabolomics
Metabolomic analysis will determine around 200 metabolites covering polar lipids (SOFIA), acylcarnitines (CARN), non-esterified fatty acids (NEFA) and amino acids (AA). Data will be acquired according to retention time and mass transition on triple quadrupole mass spectrometer, controlled by Analyst.
All metabolite concentrations are reported in µmol/L
Measured: 12 months
stool microbiome
Measured: 24 months
macronutrients in breastmilk-fat
Fat will be analysed by modified Mojonnierether extraction (g/100ml)
Measured: 6 months
macronutrients in breastmilk-Lactose
Lactose will be determined by Lactose analysis method: LC-MS/MS (g/100ml)
Measured: 6 months
macronutrients in breastmilk-protein
Protein will be determined by elemental analysis (g/100ml)
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Dec 2016 (estimated)
- Study startMar 2019 (estimated)
- Primary completionJan 2020 (estimated)
- Study completionJan 2022 (estimated)
Why it stopped: no funding
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Growth FailureStudies of the same condition, open and under way.
- More trials run by Medical University of ViennaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medical University of Vienna
- Sponsor type
- University, hospital or other
- Collaborators
- Medical University of Graz, Ludwig-Maximilians - University of Munich, University Hospital Tuebingen, University of Erlangen-Nürnberg Medical School, University of Milan, Poznan University of Medical Sciences, Lund University
- Responsible party
- Principal investigator, Nadja Haiden,MD, Medical University of Vienna
- Investigators
- Nadja Haiden, MD, Principal investigator, MUW
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02999945
- Sponsor's protocol ID
- OPTIGROW
- Acronym
- OPTIGROW
- Status last verified
- Mar 2019
- First submitted
- 5 Dec 2016
- Last updated
- 21 Mar 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 21 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Body Composition, Metabolic Programming and Long Term Outcome of Growth Restricted Preterm Infants Under Different Nutritional Management A Prospective Randomized Controlled Multicenter Trial
- ClinicalTrials.gov ID
- NCT02999945
- Acronym / sponsor ID
- OPTIGROW / OPTIGROW
- Conditions
- Growth Failure, Adiposity, Diabetes, Neurologic Deficits
- Keywords
- preterm infants, SGA infants, IUGR infants, growth, body composition, metabolomics, microbiome, adiposity markers
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: no funding
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Medical University of ViennaUniversity, hospital or other
- Collaborators
- Medical University of Graz, Ludwig-Maximilians - University of Munich, University Hospital Tuebingen, University of Erlangen-Nürnberg Medical School, University of Milan, Poznan University of Medical Sciences, Lund University
- Study start
- Mar 2019 (estimated)
- Primary completion
- Jan 2020 (estimated)
- Study completion
- Jan 2022 (estimated)
- First posted
- 21 Dec 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this prospective randomized controlled multi center trial the investigators stratify "Very Low Birthweight " (VLBW)-infants with growth retardation in small for gestational age (SGA) or intrauterine growth restricted (IUGR) - infants and aim to investigate the impact of a nutritional management with enhanced nutrients from discharge up to the 52nd week of postconceptional age on growth, body composition, metabolic programming, metabolomics, microbiome and long term neurodevelopmental outcome. In this study, the investigators will evaluate the difference in metabolic profiles of SGA and IUGR preterm infants. The investigators will further longitudinally assess, how different nutritional interventions affect the altered pathways in the first year of life and identify, in combination with data available from metabolic markers, microbiome and breast milk analysis, potential pathways resulting in increased disease risk later in life.
Detailed description
Prematurity is the leading cause for mortality and morbidity in newborns with very low birth weight (VLBW) infants (< 1500g birth weight) at highest risk. Ten to thirty percent of VLBW infants are also born too small for their gestational age defined by a birth weight below the 10th percentile. In daily neonatal intensive care, consequential long term-follow up and most studies all growth restricted premature infants are treated the same, importantly this includes the nutritional management after birth. However, different groups of patients with different causal pathologies are subsumed under the definition growth restriction or born too small. One group of growth restricted patients refers to the infants born constitutionally small or small for gestational age (SGA). The other group refers to infants with an intrauterine growth restriction (IUGR) caused by a complex antenatal pathology. Consequently, the nutritional management after birth is very important to minimize the potential risk for developing obesity, diabetes and cardiovascular diseases later in life and to achieve optimal growth. So far we do not consider the different underlying pathomechanisms of growth restriction in our nutritional concepts for preterm infants and therefore cause long-term consequences. The European society of pediatric gastroenterology, hematology and nutrition (ESPGHAN) recommends to feed enhanced nutrients up to 52nd week of gestation in all growth restricted preterm infants- regardless if they are SGA or IUGR premature. Actually, reliable data guaranteeing that the recommended "enhanced nutrients strategy" providing extra nutrients up to 52 weeks for SGA and IUGR infants is safe and effective for both groups in terms of long-term growth and metabolic programming are lacking.
A total of 348 preterm infants born and discharged below the 10th percentile at term will be included in the study and stratified according to SGA or IUGR by a combination of antenatal ultrasound parameters and growth parameters (including 10% screening failures and 20% drop out. Furthermore IUGR and SGA growth restricted preterm infants will be stratified according to breastfeeding or formula feeding and randomized in one of the following groups: Standard nutrients group (breastfeeding or starter formula) or Enhanced nutrients group (fortified breast milk or post-discharge formula. Body composition measurements will be performed by air displacement plethysmography - a non-invasive method. Anthropometric measurements will be performed by measuring weight, height and head circumference. Furthermore, parameters of metabolic programming, metabolomics, the stool microbiome and neurodevelopmental outcome will be determined. Additionally, the stool microbiome will be characterized from infant stool samples and compared between the two groups. After an interventional period of three months infants will be followed up until 2 years of age.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| SGA-enhanced nutrients | Active comparator | Dietary Supplement: SGA-enhanced nutrientsInfants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term) |
| SGA-standard nutrients | Other | Other: SGA-standard nutrientsInfants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term). |
| IUGR-enhanced nutrients | Active comparator | Dietary Supplement: IUGR-enhanced nutrientsInfants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term |
| IUGR-standard nutrients | Other | Other: IUGR-standard nutrientsInfants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term). |
Who may qualify
- Ages
- Up to 42 weeks
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- Preterm infants with a birth weight <1500g and birth weight <10th percentile.
- Weight at term <10th percentile
- Informed consent
Key exclusion criteria (6 listed)
- Genetic or metabolic diseases with the primary effect on growth
- Necrotizing enterocolitis
- Intraventricular hemorrhage (IVH) >Grade II
- Periventricular leukomalacia (PVL) Stage III
- Genetic or metabolic disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SGA-enhanced nutrientsInfants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term | Dietary supplement | SGA-enhanced nutrients |
| IUGR-enhanced nutrientsInfants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term | Dietary supplement | IUGR-enhanced nutrients |
| SGA-standard nutrientsInfants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term) | Other | SGA-standard nutrients |
| IUGR-standard nutrientsInfants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term) | Other | IUGR-standard nutrients |
Primary outcome
Fat Free Mass
Time frame: 3 months
Fat free mass measured by body plethysmography
15 secondary outcomes
anthropometry-length
Time frame: 24 months
anthropometry-weight
Time frame: 24 months
anthropometry-HC
Time frame: 24 months
anthropometry-z-score
Time frame: 24 months
parameters of metabolic programming- IGF1
Time frame: 12 months
parameters of metabolic programming-IGF3
Time frame: 12 months
parameters of metabolic programming-IGF-BP
Time frame: 12 months
parameters of metabolic programming-Leptin
Time frame: 12 months
parameters of metabolic programming-Adiponectin
Time frame: 12 months
neurodevelopmental outcome
Time frame: 24months
metabolomics
Time frame: 12 months
stool microbiome
Time frame: 24 months
macronutrients in breastmilk-fat
Time frame: 6 months
macronutrients in breastmilk-Lactose
Time frame: 6 months
macronutrients in breastmilk-protein
Time frame: 6 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Mar 2019.
- Individual participant dataSharing planned: Undecided
Related trials for Growth Failure
RecruitingPhase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Turner Syndrome, Short Stature Homeobox Gene Mutation
Active, not recruitingPhase 3
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Carcinoma, Non-Small-Cell Lung
RecruitingPhase 3
Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC
Advanced or Metastatic NSCLC
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingPhase 3
Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children
Growth Disorders, Growth Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nadja Haiden, MD principal investigator
MUW
Questions about this trial
What is this clinical trial studying?
A study testing SGA-enhanced nutrients, IUGR-enhanced nutrients and SGA-standard nutrients in people with Growth Failure and Adiposity, run by Medical University of Vienna.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 21 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fat Free Mass (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Mar 2019.